GPT and hypertensive disorder: The most commonly reported grade 3/4 AEs (≥5%) in association with pazopanib in the Phase III PALETTE trial were fatigue (14%), lymphopenia (10%) tumour pain (8%), increased alanine transaminase (ALT) (10%), increased aspartate aminotransferase (AST) (8%), hypertension (7%), dyspnoea (6%), anaemia (6%), decreased appetite (6%), and diarrhoea (5%) [18,19].